ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.